Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)|
- Tolerability of study medication [ Time Frame: 28 days ] [ Designated as safety issue: No ]
- Intraocular pressure changes [ Time Frame: 28 days ] [ Designated as safety issue: No ]
- Visual Acuity [ Time Frame: 28 days ] [ Designated as safety issue: No ]
|Study Start Date:||January 2009|
|Study Completion Date:||June 2009|
|Primary Completion Date:||June 2009 (Final data collection date for primary outcome measure)|
Active Comparator: 1
Xibrom: two times a day for seven days in the first eye.
Other Name: bromfenac
Active Comparator: 2
Nevanac: three times a day for seven days in the second eye.
Other Name: nepafenac
Open label, single armed, cross over controlled study to evaluate comfort and IOP (Intraocular Pressure) changes of specific NSAIDs post SLT. Patients (n= 25, total 50 eyes) scheduled to undergo bilateral Selective Laser Trabeculoplasty (SLT) will instill bromfenac in the first eye to undergo SLT, and the contra lateral eye will receive nepafenac.
|United States, Michigan|
|Coburn-Kleinfeldt Eye Clinic|
|3340 6 mile Rd Livonia, Michigan, United States, 48152|
|Principal Investigator:||Nate Kleinfeldt, M.D||Coburn-Kleinfeldt Eye Clinic|